Bullous pemphigoid is an autoimmune disease of the skin characterized by the production of antibodies directed at structures of the basement membrane zone (BMZ) leading to subepidermal blisters. Several causative triggers have been described in the literature, among them UV light. Here, we report on a 73-year-old Caucasian female with disseminated morphea who developed blisters on her extremities after receiving whole-body UVA-1 phototherapy. The initial differential diagnosis of a phototoxic versus photoallergic reaction was ruled out as the lesions continued to spread after discontinuation of phototherapy. Histological and direct immunofluorescence examination showing a subepidermal blister and linear IgG deposits along the BMZ along with detection of circulating anti-BMZ antibodies led to the diagnosis of bullous pemphigoid. Immunosuppressive therapy resulted in regression of all blisters. After ruling out other possible causes, such as neoplasias or drugs, we conclude that UVA-1 has to be regarded as the most likely trigger of the disease.

1.
Lever WF: Pemphigus. Medicine (Baltimore) 1953;32:1.
2.
Bird P, Friedmann PS, Ling N, Bird AG, Thompson RA: Subclass distribution of IgG autoantibodies in bullous pemphigoid. J Invest Dermatol 1986;86:21–25.
3.
Bernard B, Bedane C, Bonnetblanc JM: Anti-BP180 autoantibodies as a marker of poor prognosis of BP: A cohort analysis of 94 elderly patients. Br J Dermatol 1997;136:694–697.
4.
Lever WF, Schaumburg-Lever G: Histopathology of the skin. Philadelphia, Lippincott, 1990, chapter 7: Noninfectious vesicular and bullous diseases, pp 103–151.
5.
Korman NJ: Bullous pemphigoid. Dermatol Clin 1993;11:483–498.
6.
Liu Z, Giudice GJ, Swartz SJ, Fairley JA, Till GO, Troy IL, Diaz LA: The role of complement in experimental bullous pemphigoid. J Clin Invest 1995;95:1539–1544.
7.
Jablonska S, Chorzelski TP, Blasczyk M, Maciejowska E: Bullous diseases and malignancy. Semin Dermatol 1984;3:316–326.
8.
Fellner MJ, Katz JM: Occurrence of bullous pemphigoid after furosemide therapy. Arch Dermatol 1976;112:75–77.
9.
Mallet L, Cooper JW, Thomas J: Bullous pemphigoid associated with captopril. DICP 1989;23:63.
10.
Weller R, White MI: Penicillamine in the etiology of bullous pemphigoid. Ann Pharmacother (United States) 1998;32:1368.
11.
Grange F, Scrivener Y, Koessler A, Straub P, Guillaume JC: Spironolactone-induced pemphigoid. Ann Dermatol Venereol 1997;124:700–702.
12.
Pfau A, Hohenleutner U, Hohenleutner S, Eckert F, Landthaler M: UV-A-provoked localized bullous pemphigoid. Acta Derm Venereol (Stockh) 1994;74:314–316.
13.
Perl S, Rappersberger K, Födinger D, Anegg B, Hönigsmann H, Ortel B: Bullous pemphigoid induced by PUVA therapy. Dermatology 1996;193:245–247.
14.
Thomsen K, Schmidt H: PUVA-induced bullous pemphigoid. Br J Dermatol 1976;95:568–569.
15.
Lee CW, Ro YS: Sun-induced localized bullous pemphigoid. Br J Dermatol 1992;126:91–92.
16.
Preeman AH, Toonstra J, Van der Putte SC: UV-B-induced bullous pemphigoid restricted to mycosis fungoides plaques. Clin Exp Dermatol 1990;15:363–366.
17.
Duschet P, Schwarz T, Gschnait F: Bullous pemphigoid after radiation therapy. J Am Acad Dermatol 1988;18:441–444.
18.
Burns DA, Sakarny I: Generalized morphea with bullous lesions and psoriasis. Br J Dermatol 1976;95(suppl 14):33–34.
19.
Jappe E, Zillikens D, Bonnekoh B, Gollnick H: Epidermolysis bullosa acquisita with ultraviolet radiation sensitivity. Br J Dermatol 2000;142:517–520.
20.
Jordan RE, Kawana S, Fritz KA: Immunologic mechanism in pemphigus and bullous pemphigoid. J Invest Dermatol 1985;suppl 85:72–78.
21.
Luger TA, Schwarz T: Evidence for epidermal cytokine network. J Invest Dermatol 1990;95:100S–104S.
22.
Kumar V, Binder WL, Schotland E, Beutner EH, Chorzelski TP: Coexistence of bullous pemphigoid and systemic lupus erythematosus. Arch Dermatol 1978;114:1187–1190.
23.
Koerber WA Jr, Price NM, Watson W: Coexistent psoriasis and bullous pemphigoid. Arch Dermatol 1978;114:1643–1646.
24.
Chorzelski TP, Maciejowski E, Jablonska S, DeMento FJ, Grover RW, Holubar K, Beutner EH: Coexistence of pemphigus and bullous pemphigoid. Arch Dermatol 1974;109:849–853.
25.
Harrington CI, Sneddon IB: Coexistence of bullous pemphigoid and pemphigus foliaceus. Br J Dermatol 1979;100:441–445.
26.
Bernstein JE, Medenica M, Soltani K: Coexistence of localized bullous pemphigoid, morphea, and subcorneal pustulosis. Arch Dermatol 1981;117:725–727.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.